A single arm, prospective study to determine safety and efficacy of Syrup Urophyll, 10 ml three times a day in patients diagnosed with chronic kidney disease and not on dialysis.

The Investigational Product (IP) which is Syrup Urophyll is an approved and marketed adjuvant and an anti-oxidant product. It has sodium-copper-chlorophyllin as the main ingredient along with sorbitol, glycerin etc. It is approved and marketed as a food ingredient having fssai license number: 11513029000653. The proposed study is to see the safety and efficacy of the IP in patients with compromised kidney functions. All the patients enrolled in the study will get the IP. No medicine which his/her physician is giving/intends to give will be stopped. Thus, patients enrolled in the study will get the IP in addition to the standard of care, otherwise the patient would have received. Known and old patients of CKD, who are already on medications, will also be enrolled if they are eligible and willing. Their regular medicines will not be stopped or altered due to their participation in the study. They also will be getting IP in addition to their routine standard of care. Though study period for enrolled patients is 3 months, IP will be given for 2 months only. Thus patients will be off the IP for last 30 days, though the standard of care or regular medicines will be continued throughout. The IP may help reduce serum creatinine, increase the glomerular filtration rate (GFR) and thus benefit patients manage their CKD in a better manner. As participants will be given the standard of care which otherwise might have been given to them. Hence they are not deprived ethically of their right of standard of care.